Science4Data Article Insights

https://news.sky.com/story/coronavirus-oxford-vaccine-could-provide-double-protection-report-12029406?dcmp=snt-sf-twitter

Coronavirus: Oxford vaccine could provide 'double protection'

2020-07-17 20:53:18, , Sky News

Content Categorization
/Health/Public Health
/Health/Health Conditions/Infectious Diseases
/Law & Government/Public Safety

Word Count:
414

Words/Sentence:
30

Reading Time:
2.76 min

Reading Quality:
Adept

Readability:
13th to 15th

Media Sentiment
Proprietary sentiment analysis on both the headline and body text of the article. Sentiment scores range from -1 (very negative sentiment) to 1 (very positive sentiment).
RCS Analysis
Relative scoring for Risk, Crisis, and Security language within the article.
Risk Score
Scoring based on the composite risk, security and crisis language within an article compared to a baseline of historic analysis across thousands of diverse articles.
PESTEL Scope
Analysis of article orientation across the PESTEL macro-environmental analysis framework. Learn more about PESTEL.
Entity Word Cloud
Key people, places, organizations and events referenced in the article, weighted by frequency and colored based on contextual sentiment.
Auto Summary
Condensing key features of the article based on salience analysis. Helpful for “gisting” the article in a time crunch.

Human trials are reported to have shown promising results after the team discovered the jab could provide "double protection" against the virus.

Blood samples taken from volunteers in phase one trials have shown the vaccine stimulated the body to produce antibodies and T-cells, according to a report in The Daily Telegraph.T-cells play a central part in the body's immune response.

Image:

There are high hopes for the vaccine being developed at Oxford and another at Imperial College

The pharmaceutical company's chief executive said last month that phase one trials were due to finish and a phase three trial had begun which will see the vaccine given to thousands of people so it can be tested for efficacy and safety.

:: Listen to the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, SpreakerThe vaccine is based on a weakened version of the common cold that causes infections in chimpanzees.

The vaccine is one of more than 100 in development as the coronavirus continues to spread – infecting more than 13 million people and killing at least 582,000.

David Carpenter, chairman of the Berkshire Research Ethics Committee, which approved the Oxford trial, said the vaccine team was "absolutely on track".

He added: "Nobody can put final dates… things might go wrong but the reality is that by working with a big pharma company, that vaccine could be fairly widely available around September and that is the sort of target they are working on."

The firm has reached agreements to supply around two billion doses worldwide, despite acknowledging that it is not yet certain the vaccine will work.

Keywords

Interested in Learning More?

Article Analysis is at the foundation of powerful media monitoring and insights. Learn what you can build with powerful curated search engines, real-time listening and trend analysis on the topics, markets and companies critical to your organization.